CLAIMS

1. The use of a compound containing a high density, negatively charged domain of vicinally oriented radicals for the preparing of a medicament providing a growth factor modulating activity in mammals including man.

2. The use according to claim 1 wherein the negatively charged domain comprises at least three vicinal phosphorus-containing radicals.

3. The use according to claim 1 wherein the phosphorus-containing radicals have the following formula:

a) b)



wherein
V^1 to V^4 are $Y^8{}_{m6}T_{o3}U$
T_{o1} to T_{03} are $(CH_2)_n$, CHCH, or $CH_2CHCHCH_2$,
o1 to o3 are 0 or 1
n is 0 to 4;
U is $R^1Y^9{}_{m7}$, $CY^{10}Y^{11}R^2$, $SY^{12}Y^{13}Y^{14}R^3$, $PY^{15}Y^{16}Y^{17}R^4R^5$, $Y^{18}PY^{19}Y^{20}Y^{21}R^6R^7$, CH_2NO_2, $NHSO_2R^8$, or $NHCY^{22}Y^{23}R^9$;
m1 to m7 are 0 or 1;
Y^1 to Y^{23} are NR^{10}, NOR^{11}, O, or S;
and where R^1 to R^{11} are

i) hydrogen
ii) a straight or branched saturated or unsaturated alkyl residue containing 1-22 carbon atoms
iii) a saturated or unsaturated aromatic or non-aromatic homo- or heterocyclic residue containing 3-22 carbon atoms and 0-5 heteroatoms consisting or nitrogen, oxygen or sulfur

iv) a straight or branched saturated or unsaturated alkyl residue containing 1-22 carbon atoms substituted with a saturated or unsaturated aromatic or non-aromatic homo- or heterocyclic residue containing 3-22 carbon and 0-5 heteroatoms consisting of nitrogen, oxygen, or sulfur

v) an aromatic or non-aromatic homo- or heterocyclic residue containing 3-22 carbon and 0-5 heteroatoms consisting of nitrogen, oxygen, or sulfur substituted with a straight or branched saturated or unsaturated alkyl residue containing 1-22 carbon atoms

in the said groups ii-v the residues and/or the substituents thereof being substituted with 0-6 of the following groups: hydroxy, alkoxy, aryloxy, acyloxy, carboxy, alkoxycarbonyl, alkoxycarbonyloxy, aryloxycarbonyl, aryloxycarbonyloxy, carbamoyl, fluoro, chloro, bromo, azido, cyano, oxo, oxa, amino, imino, alkylamino, arylamino, acylamino, arylazo, nitro, alkylthio or alkylsulfonyl.

4. The use according to claim 3 wherein the phosphorus-containing radicals have the following formula:



wherein V^1 and V^2 are OH, $(CH_2)_pOH$, COOH, $CONH_2$, CONOH, $(CH_2)_pCOOH$, $(CH_2)_pCONH_2$, $(CH_2)_pCONOH$, $(CH_2)_pSO_3H$, $(CH_2)_pSO_3NH_2$, $(CH_2)_pNO_2$, $(CH_2)_pPO_3H_2$, $O(CH_2)_pOH$, $O(CH_2)_pCOOH$, $O(CH_2)_pCONH_2$, $O(CH_2)_pCONOH$, $O(CH_2)_pSO_3H$, $O(CH_2)_pSO_3NH_2$, $O(CH_2)_pNO_2$, $O(CH_2)_pPO_3H_2$ or CF_2COOH
p is 1 to 4

5. The use according to claim 3 wherein the phosphorus-containing radicals are phosphate groups.

6. The use according to claim 1 wherein a backbone to the high density negatively charged region of vicinally oriented radicals is a cyclic moiety.

7. The use according to claim 6 wherein the backbone is a saturated or unsaturated aromatic or non-aromatic homo- or heterocyclic moiety where the heteroatom is nitrogen, oxygen, sulfur or selenium.

8. The use according to claim 7 wherein the cyclic moiety comprises 4 to 24 atoms, preferably 5 to 18 atoms.

9. The use according to claim 7 wherein the cyclic moiety is selected from the group of cyclopentane, cyclohexane, cycloheptane, inositol, monosacharide, disacharide, trisacharide, tetrasacharide, piperidin, tetrahydrothiopyran, 5-oxotetrahydrothiopyran, 5,5-dioxotetrahydrothiopyran, tetrahydroselenopyran, tetrahydrofuran, pyrrolidine, tetrahydrothiophene, 5-oxotetrahydrothiophene, 5,5-dioxotetrahydrothiophene, tetrahydroselenophene, benzene, cumene, mesitylene, naphtalene and phenanthrene.

10. The use according to claim 7 wherein the cyclic moiety is selected from the group of alloinositol, cisinositol, ipiinositol, D/L-chiroinositol, scylloinositol, myoinositol, mycoinositol and neoinositol.

11. The use according to claim 7 wherein the cyclic moiety is selected from the group of D/L-ribose, D/L-arabinose, D/L-xylose, D/L-lyxose, D/L-allose, D/L-altrose, D/L-glucose, D/L-mannose, D/L-gulose, D/L-idose, D/L-galactose, D/L-talose, D/L-ribulose, D/L-xylulose, D/L-psicose, D/L-sorbose, D/L-tagatose, and D/L-fructose.

12. The use according to claim 7 wherein one of the phosphorus-containing radicals is axial and two of the phosphorus-containing radicals are equatorial.

13. The use according to claim 12 wherein the compound is selected from the group of myo- inositol-1,2,6-trisphosphate, mannose-2,3,4-trisphosphate, rhamnose-2,3,4-trisphosphate, galactose, 2,3,4-trisphosphate, methyl-6-O-butyl-α-D-manno pyranoside-2,3,4-trisphosphate 1,5-anhydro-D-arabinitol--2,3,4-trisphosphate fructose-2,3,4-trisphosphate, 1,2-O-ethylene-ß-D-fructpyranoside-2,3,4-trisphosphate, cyclohexane-1,2,3-triol trisphosphate, 1,5-dideoxy-1,5-iminoarabinitol-2,3,4-trisphosphate, altrose-2,3,4-trisphosphate, methyl-6-O-butyl-α-D-altropyranoside 2,3,4-trisphosphate or derivatives thereof.

14. The use according to claim 1 wherein the compound is administered by parenteral or non-parenteral administration.

15. The use according to claim 1 wherein the effective amount is from about 0.1 to about 100 mg per kg bodyweight of the animal or man.

16. The use according to claim 1 wherein the agent is in unit dosage forms comprising tablets, granules, capsules, solutions or suspensions.

17. A process of modulating growth factor activity by using a compound according to claims 1-16.